[go: up one dir, main page]

AU5873498A - Mutant (msbb) or (htrb) genes - Google Patents

Mutant (msbb) or (htrb) genes

Info

Publication number
AU5873498A
AU5873498A AU58734/98A AU5873498A AU5873498A AU 5873498 A AU5873498 A AU 5873498A AU 58734/98 A AU58734/98 A AU 58734/98A AU 5873498 A AU5873498 A AU 5873498A AU 5873498 A AU5873498 A AU 5873498A
Authority
AU
Australia
Prior art keywords
msbb
htrb
mutant
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58734/98A
Inventor
Gordon Dougan
Duncan John Maskell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College of London
Original Assignee
Imperial College of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9701886.5A external-priority patent/GB9701886D0/en
Priority claimed from GBGB9701887.3A external-priority patent/GB9701887D0/en
Application filed by Imperial College of London filed Critical Imperial College of London
Publication of AU5873498A publication Critical patent/AU5873498A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU58734/98A 1997-01-30 1998-01-30 Mutant (msbb) or (htrb) genes Abandoned AU5873498A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9701886.5A GB9701886D0 (en) 1997-01-30 1997-01-30 Nucleic acid
GB9701887 1997-01-30
GBGB9701887.3A GB9701887D0 (en) 1997-01-30 1997-01-30 Nucleic acid
GB9701886 1997-01-30
PCT/GB1998/000291 WO1998033923A1 (en) 1997-01-30 1998-01-30 MUTANT msbB or htrB GENES

Publications (1)

Publication Number Publication Date
AU5873498A true AU5873498A (en) 1998-08-25

Family

ID=26310892

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58734/98A Abandoned AU5873498A (en) 1997-01-30 1998-01-30 Mutant (msbb) or (htrb) genes

Country Status (3)

Country Link
EP (1) EP0973911A1 (en)
AU (1) AU5873498A (en)
WO (1) WO1998033923A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012232B1 (en) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ATE534402T1 (en) 2000-06-29 2011-12-15 Smithkline Beecham Biolog MULTIVALENT VACCINE COMPOSITION
TWI457133B (en) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR101856736B1 (en) * 2016-02-29 2018-05-11 (주)비손바이오로직스 Endotoxin-reduced Salmonella trivalent inactivated vaccine composition for preventing fowl typhoid and Salmonellosis
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
KR102264989B1 (en) * 2019-05-31 2021-06-15 강원대학교 산학협력단 Endotoxin-reduced Escherichia coli trivalent inactivated vaccine composition for preventing Avian colibacillosis
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US20220395565A1 (en) * 2021-05-26 2022-12-15 Seoul National University R&Db Foundation Attenuated salmonella gallinarum mutant strains and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria

Also Published As

Publication number Publication date
WO1998033923A1 (en) 1998-08-06
EP0973911A1 (en) 2000-01-26

Similar Documents

Publication Publication Date Title
AU5873498A (en) Mutant (msbb) or (htrb) genes
AU8116494A (en) Gene signature
AU1797799A (en) Impedance-heated furnace
AU2037400A (en) Software vault
AU3972893A (en) Gene therapy using the intestine
AU7582298A (en) Tissue specific prodrug
AU6672794A (en) Antineoplastic heteronaphthoquinones
AU6784598A (en) Medical plug
AU4092996A (en) Stabilizer combination
AU5198398A (en) Mutant human hedgehog gene
AU6508898A (en) Improved display
AU6822396A (en) Pigment stabilization
AU4786696A (en) Connectors
AU6659998A (en) Tazarotene-induced gene 3 (tig3)
AU5944898A (en) Catheter
AU4786596A (en) Connectors
AU2965199A (en) Medicine mini-chest
AU7122196A (en) Rotary furnace
AU3934395A (en) Enzyme stabilization
AU3186995A (en) Furnace
AU6342696A (en) The caip-like gene family
AUPN224995A0 (en) Pre-mix chamber
AU709402C (en) Improved forages
AUPO860897A0 (en) Differential turning sole
AUPO675597A0 (en) Bushranger wheelchair